Free tool
FAERS Monitor: Hydrocortisone Acetate
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 009637 or its brand name (Hydrocortisone Acetate, Hydrocortisone Acetate). Reports on generic versions are filed under their own applications.
Reports
5,445
Serious
4,776
88% of reports
Hospitalization
2,559
Death reported
1,614
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective2,145
- fatigue2,011
- pain1,988
- abdominal discomfort1,985
- systemic lupus erythematosus1,952
- rash1,933
- alopecia1,914
- rheumatoid arthritis1,845
- swelling1,835
- glossodynia1,823
- pemphigus1,822
- hepatic enzyme increased1,790
- hand deformity1,781
- infusion related reaction1,766
- arthropathy1,756
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 7 |
| 2005 | 15 |
| 2006 | 54 |
| 2007 | 15 |
| 2008 | 11 |
| 2009 | 18 |
| 2010 | 19 |
| 2011 | 20 |
| 2012 | 48 |
| 2013 | 29 |
| 2014 | 51 |
| 2015 | 71 |
| 2016 | 94 |
| 2017 | 91 |
| 2018 | 147 |
| 2019 | 218 |
| 2020 | 315 |
| 2021 | 749 |
| 2022 | 898 |
| 2023 | 760 |
| 2024 | 855 |
| 2025 | 642 |
| 2026 | 318 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,714 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pemphigusSignal | 1,822 | 658.7 | 631.7 | 1,022,417 |
| hand deformitySignal | 1,781 | 606.6 | 581.5 | 930,860 |
| glossodyniaSignal | 1,823 | 342.3 | 329.0 | 570,270 |
| systemic lupus erythematosusSignal | 1,952 | 224.7 | 216.5 | 411,378 |
| arthropathySignal | 1,756 | 126.0 | 121.1 | 211,265 |
| infusion related reactionSignal | 1,766 | 105.7 | 101.6 | 178,737 |
| hepatic enzyme increasedSignal | 1,790 | 104.1 | 100.2 | 178,506 |
| swellingSignal | 1,835 | 77.2 | 74.4 | 135,899 |
| rheumatoid arthritisSignal | 1,845 | 63.8 | 61.4 | 112,735 |
| abdominal discomfortSignal | 1,985 | 46.2 | 44.6 | 87,481 |
| alopeciaSignal | 1,914 | 38.0 | 36.7 | 68,905 |
| rashSignal | 1,933 | 17.2 | 16.6 | 29,971 |
| painSignal | 1,988 | 12.5 | 12.1 | 21,662 |
| fatigueSignal | 2,011 | 10.0 | 9.7 | 16,864 |
| drug ineffectiveSignal | 2,145 | 6.3 | 6.1 | 10,171 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.